Raymond James & Associates Brooklyn Immuno Therapeutics, Inc. Transaction History

Raymond James & Associates

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.48 - $2.03 $15,600 - $65,975	-32,500 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.76 - $4.84 $325,600 - $895,400	-185,000 Reduced 85.06%	32,500 $67,000
Q4 2021 Feb 08, 2022	BUY	$4.17 - $9.79 $906,975 - $2.13 Million	217,500 New	217,500 $907,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.